Stemline Therapeutics Stock Price (NASDAQ:STML)

Add to My Stocks
$6.95 $0.15 (2.21%) STML stock closing price Feb 21, 2017 (Closing)
YOUR DAILY UPDATE ON
STML
Stemline Therapeutics
21 FEB 2017
amigobulls logo
STML hand_up
STML vs S&P 500
Closing Price: Feb 21, 2017
STML
$6.95 ( 2.21%)
S&P 500
2365.4 ( 0.6%)
STML
52 Week Price Range
1 Year Return: 60%
Q3 Growth*
Excellent
Profitable ?
No
net image
2016 Q3 Net Loss
-4007.3%
home image
Rating
STML POOR
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen
0:00
/

Stemline Therapeutics Snapshot Video

12 5 2

STML Stock Details

Prev Close* : $6.80
Market Cap:
$160.83M
Day Low: $6.8
52 Week Low: $3.88
Open: $7.15
Volume: 557560
Day High: $7.45
52 Week High: $14.60
Dividend:
N/A

Latest Stock Market News

Latest Articles

Stemline Therapeutics News - From Partners

STML Stockcharts

View STML PE ratio, PS ratio stocks charts and compare with peers.
STML Chart
Note: Compare Stemline Therapeutics stock price history with the index and industry peers.

Stemline Therapeutics Valuation

PS ratio (
price to sales ratio
)
129.08
PB ratio (
price to book ratio
)
1.53

Stemline Therapeutics Financial Ratios

Asset Turnover
0.02

STML Industry Peers

Company Price Change (%)
Kadmon Holdings (KDMN)40 (0%)
Cellular Biomedicine (CBMG)12.050.25 (2.03%)
Karyopharm Therapeutics (KPTI)10.580.02 (0.19%)
Celgene (CELG)119.441.72 (1.42%)
Agenus (AGEN)4.540.03 (0.67%)
Immunocellular Therapeutics (IMUC)2.70.02 (0.74%)
Seattle Genetics (SGEN)65.680.18 (0.27%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
EXACT Sciences (EXAS)22.412.5 (12.56%)
Fate Therapeutics (FATE)4.380.45 (11.45%)
Nymox Pharmaceutical (NYMX)3.540.12 (3.51%)
Myriad Genetics (MYGN)19.080.46 (2.47%)
Stemline Therapeutics (STML)6.950.15 (2.21%)
Evogene (EVGN)5.4210.11 (2.07%)
OncoMed Pharma (OMED)8.910.18 (2.06%)
Top gainers from Medical-Biomed-Genetics industry
* As of Feb 21, 2017
CompanyPriceChange (%)
Trevena (TRVN)4.272.86 (40.11%)
Momenta Pharma (MNTA)16.052.95 (15.53%)
Peregrine Pharma (PPHM)0.4790.07 (12.73%)
Cytokinetics (CYTK)10.40.85 (7.56%)
Argos Therapeutics (ARGS)4.40.3 (6.38%)
Sorrento Therapeutics (SRNE)5.250.3 (5.41%)
Immunomedics (IMMU)5.060.28 (5.24%)
Top losers from Medical-Biomed-Genetics industry
* As of Feb 21, 2017

Stemline Therapeutics Financial Statements

income statement20152014201320122011
Net Sales Or Revenues0.65M0.33M0.07M--
Net Income-37.24M-28.82M-24.19M-6.27M-2.75M
Total Operating Expense38.27M29.32M24.04M6.46M2.7M
view Stemline Therapeutics Inc income statement
balance sheet20152014201320122011
Total Assets98.21M60.49M85.28M5.02M6.45M
Total Liabilities10.1M5.08M5.65M7.53M3.24M
Shareholders Equity88.11M55.41M79.62M-2.5M3.2M
view Stemline Therapeutics Inc balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities6M-1.71M2.66M1.53M0.6M
Net Cash From (Used By) Operating Activities-25.58M-25.71M-16.11M-4.12M-1.93M
Increase (Decrease) In Prop Plant And Equipment-0.01M--0.46M--
view Stemline Therapeutics Inc cashflow statement

Stemline Therapeutics Inc Stock News - Partner Headlines

Stemline Therapeutics Stock Message Board

Stemline Therapeutics stock lost 6.25 %, and the last close price as of 17 Feb, 2017 is 6.8 for STML stock. Looking at Stemline Therapeutics market capitalization, which currently stands at 160.83M, we can say that STML stock is a Micro cap stock. A value investor must look at the fundamentals of a stock, and perform Stemline Therapeutics valuation, even though in the short-term sentiment and current breaking news might affect Stemline Therapeutics stock price.

For recognizing and analyzing the real performance of Stemline Therapeutics stock, it is a standard practise to adjust historical stock prices to remove gaps caused by stock splits, dividends and distributions. 207347 STML shares were traded yesterday, and Stemline Therapeutics stock chart shows that the STML stock quote hit a day high of 6.8 and day low of 6.4. One can observe stock price trends and check for volatility by checking Stemline Therapeutics stock price history.